Abstract
Fifty-eight evaluable patients with acute leukemia were treated with Mitoxantrone (DHAD) according to two schedules: 14 mg/M2 as a single I.V. pulse dose administered three-week intervals, and 4 mg/M2/day for five days every three weeks. Six of 58 patients achieved a complete remission. One complete remission and 1 partial remission were observed among 26 patients treated with the single pulse schedule. Five (16%) complete remissions were attained among 32 patients treated on the daily × 5 schedule. Responses were observed only in patients with non-lymphoblastic leukemia. DHAD was very well tolerated with myelosuppression as the major toxicity. Nausea and vomiting were minimal. Subclinical cardiac toxicity occurred in two patients. This was identified by serial reductions in cardiac ejection fractions. DHAD appears to have significant activity in acute non-lymphoblastic leukemia with minimal toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
See-Cheng RKY, Cheng CC: Antineoplastic agents. Structure activity relationship of bis(substituted aminoalkylamine) anthraquinones. J Med Chem 21:291–294, 1978
Johnson RK, See-Cheng RKY, Lee WW, Acton FM, Henry DW, Cheng CC: Experimental antitumor activity of amino anthraquinones. Ca Treat Rep 63:425–439, 1979
Coltman CA, Saiki JH, Panettiere FJ, Balcerzak SP, Stephens RL, Morrison FS, Dixon DO: Mitoxantrone hydrochloride in hematologic malignancies: Southwest Oncology Group phase II studies. In: Rozencweiget al. (ed.): New anticancer drugs: Mitoxantrone and Bisantrene. New York, Raven Press, 1983, pp 115–124
Von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman CA Jr: Phase I Clinical Investigation of 1,4-dihydroxy-5,8-bis(2-2-hydroxyethyl) amino(ethyl(amino))-9, 10-anthracenedionedihydrochloride (NSC 301739), A New Anthracendedione. Cancer Res 40:1516–1518, 1980
Prentice HG, Robbins G, Ma DDF, Ho AD: Sequential Studies on The Role of Mitoxantrone in The Treatment of Acute Leukaemia, Cancer Treat Rev 10:57–63, 1983
Larson RA, Daly KM, Choi KE, Han DS, Sinkule JA: A Clinical and Pharmacokinetic Study of Mitoxantrone in Acute Nonlymphocytic Leukemia. Jr of Clin One 5:391–397, 1987
Van Echo DA, Shulman PN, Ferrari A, Budman D, Markus SK, Wiernik PH: A phase II trial of Mitoxantrone (DHAD, NSC-301739) in adult acute leukemia. ASCO Proceedings 18:132, 1982
Paciucci PA, Ohnuma T, Cuttner J, Silver RT, Holland JF: Mitoxantrone in patients with acute leukemia in relapse. Ca Res 43:3919–3922, 1983
Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ: Phase II trial of dihydroxyanthracenedione in acute leukemia. AACR Proceedings 73:113, 1982
Wynert WR, Harver HA, Lipton A, Schweitzer J, White DS: Phase I study of a 5-day schedule of Mitoxantrone (Di-hydroxyanthracenedione). Ca Treat Rep 66:1303–1306, 1982
Stewart JA, McCormack JJ, Krakoff IH: Clinical and clinical pharmacologic studies of Mitoxantrone. Ca Treat Rep 66:1327–1331, 1982
Van Echo DA, Whitacre MY, Aisner J, Wiernik PH: Phase I trial of dihydroxyanthracenedione. Ca Treat Rep 64:831–834, 1981
Valdivieso M, Bedikian AY, Burgess MA, Savaraj N, Jeffers WB, Bodey GP: Phase I clinical study of dihydroxyan-thracenedione administered on a 5-day I.V. schedule. Ca Treat Rep 65:841–844, 1981
Aapro M, Mackel C, Alberts D, Woolfenden J: Phase II cardiotoxicity study of Mitoxantrone Hydrochloride using exercise radionuclide evaluation of the left ventricular cardiac ejection fraction. ASCO Proceedings 18:14, 1982
Schell FC, Yap HY, Blumenschein GR, Bodey GP: Potential cardiotoxicity observed with dihydroxyanthracenedione (DHAD). AACR Proceedings 73:110, 1982
Anderson KC, Cohen G, Garnick MB, Meshad M, Canellos GP: A phase II study of dihydroxyanthracenedione (DHAD). AACR Proceedings 73:110, 1982
Knight WA III, Von Hoff DD, Tranum B, O'Bryan R: Phase II trial of dihydroxyanthracenedione (DHAD, Mitoxantrone) in breast cancer. ASCO Proceedings 18:87, 1982
Callahan SK, Von Hoff DD, Clark GM, Chen T, Mira J, Livingston R: Mitoxantrone for oat cell carcinoma of the lung:In vivo and in vitro results. ASCO Proceedings 18:153, 1982
Taylor SA, Von Hoff DD: Phase II trial of dihydroxyanthracenedione (DHAD) in advanced renal cell carcinoma. ASCO Proceedings 18:118, 1982
Cowan J, Von Hoff DD, McDonald B, Talley R, McCracken J: Phase II evaluation of Mitoxantrone in previously untreated patients with colorectal cancer. ASCO Proceedings 18:99, 1982
Neidhart JA, Roach RW: A randomized study of Mitoxantrone and Adriamycin in breast cancer patients failing primary therapy. ASCO Proceedings 18:86, 1982
Bonnem E, Mitchell E, Smith F, Bowers MW, Neefe JL, Brereton H, Winokur S, Haidak D, DeGreen P, Schein P, Woolley P: A phase II trial of dihydroxyanthracenedione (DHAD) in advanced colon cancer. ASCO Proceedings 18:97, 1982
Valdivieso M, Umsawasdi T, Spitzer G, Bodey GP: Phase II clinical study of dihydroxyanthracenedione (DHAD) in patients with advanced lung cancer. ASCO Proceedings 18:145, 1982
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Saiki, J.H., Stuckey, W.J., Athens, J.W. et al. Mitoxantrone (dihydroxyanthracenedione) in acute leukemia. Invest New Drugs 11, 197–200 (1993). https://doi.org/10.1007/BF00874154
Issue Date:
DOI: https://doi.org/10.1007/BF00874154